As a central regulator of major physiological processes, the pituitary gland is a highly dynamic organ, capable of responding to hormonal demand and hypothalamic influence, through adapting secretion as well as remodelling cell numbers among its seven populations of differentiated cells. Stem cells of the pituitary have been shown to actively generate new cells during postnatal development but remain mostly quiescent during adulthood, where they persist as a long-lived population. Despite a significant body of research characterising attributes of anterior pituitary stem cells, the regulation of this population is poorly understood. A better grasp on the signalling mechanisms influencing stem proliferation and cell fate decisions can impact on our future treatments of pituitary gland disorders such as organ failure and pituitary tumours, which can disrupt endocrine homeostasis with life-long consequences. This minireview addresses the current methodologies aiming to understand better the attributes of pituitary stem cells and the normal regulation of this population in the organ, and discusses putative future avenues to manipulate pituitary stem cells during disease states or regenerative medicine approaches.

Keywords:
Pituitary stem cell, SOX2, YAP/TAZ, Hippo, Regenerative medicine
1.
Andoniadou CL, et al: Sox2+ stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential. Cell Stem Cell 2013; 13: 433–445.
2.
Aguayo-Mazzucato C, Bonner-Weir S: Pancreatic β cell regeneration as a possible therapy for diabetes. Cell Metab 2018; 27: 57–67.
3.
Gaston-Massuet C, et al: Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans. Proc Natl Acad Sci USA 2011; 108: 11482–11487.
4.
Roose H, et al: Major depletion of SOX2+ stem cells in the adult pituitary is not restored which does not affect hormonal cell homeostasis and remodelling. Sci Rep 2017; 7: 16940.
5.
Fu Q, Vankelecom H: Regenerative capacity of the adult pituitary: multiple mechanisms of lactotrope restoration after transgenic ablation. Stem Cells Dev 2012; 21: 3245–3257.
6.
Waite E, et al: Different degrees of somatotroph ablation compromise pituitary growth hormone cell network structure and other pituitary endocrine cell types. Endocrinology 2010; 151: 234–243.
7.
Ozone C, Suga H: Functional pituitary tissue formation. Methods Mol Biol 2017; 1597: 57–65.
8.
Ozone C, et al: Functional anterior pituitary generated in self-organizing culture of human embryonic stem cells. Nat Commun 2016; 7: 10351.
9.
Dincer Z, et al: Specification of functional cranial placode derivatives from human pluripotent stem cells. Cell Rep 2013; 5: 1387–1402.
10.
Suga H, et al: Self-formation of functional adenohypophysis in three-dimensional culture. Nature 2011; 480: 57–62.
11.
Leung AW, Kent Morest D, Li JY: Differential BMP signaling controls formation and differentiation of multipotent preplacodal ectoderm progenitors from human embryonic stem cells. Dev Biol 2013; 379: 208–220.
12.
Zimmer B, et al: Derivation of diverse hormone-releasing pituitary cells from human pluripotent stem cells. Stem Cell Reports 2016; 6: 858–872.
13.
Falconi G, Rossi GL: Method for placing a pituitary graft into the evacuated pituitary capsule of the hypophysectomized rat or mouse. Endocrinology 1964; 75: 964–967.
14.
Maxwell M, et al: Functional transplantation of the rat pituitary gland. Neurosurgery 1998; 43: 1157–1163.
15.
Tulipan NB, Zacur HA, Allen GS: Pituitary transplantation: part 1. Successful reconstitution of pituitary-dependent hormone levels. Neurosurgery 1985; 16: 331–335.
16.
Vuillez P, Moos F, Stoeckel ME: Immuno-cytochemical and ultrastructural studies on allografts of the pituitary neurointermediate lobe in the third cerebral ventricle of the rat. Cell Tissue Res 1989; 255: 393–404.
17.
Arnold K, et al: Sox2+ adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell 2011; 9: 317–329.
18.
Jayakody SA, et al: SOX2 regulates the hypothalamic-pituitary axis at multiple levels. J Clin Invest 2012; 122: 3635–3646.
19.
Gremeaux L, et al: Activated phenotype of the pituitary stem/progenitor cell compartment during the early-postnatal maturation phase of the gland. Stem Cells Dev 2012; 21: 801–813.
20.
Mollard P, et al: A tridimensional view of pituitary development and function. Trends Endocrinol Metab 2012; 23: 261–269.
21.
Rizzoti K, Akiyama H, Lovell-Badge R: Mobilized adult pituitary stem cells contribute to endocrine regeneration in response to physiological demand. Cell Stem Cell 2013; 13: 419–432.
22.
Lepore DA, et al: Identification and enrichment of colony-forming cells from the adult murine pituitary. Exp Cell Res 2005; 308: 166–176.
23.
Andoniadou CL, et al: Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma. Acta Neuropathol 2012; 124: 259–271.
24.
Garcia-Lavandeira M, et al: Craniopharyngiomas express embryonic stem cell markers (SOX2, OCT4, KLF4, and SOX9) as pituitary stem cells but do not coexpress RET/GFRA3 receptors. J Clin Endocrinol Metab 2012; 97:E80–E87.
25.
Weiss S, et al: Evidence for a progenitor cell population in the human pituitary. Clin Neuropathol 2009; 28: 309–318.
26.
Kikuchi M, et al: Immunohistochemical localization of anterior pituitary hormones in S-100 protein-positive cells in the rat pituitary gland. Cell Tissue Res 2011; 345: 425–429.
27.
Garcia-Lavandeira M, et al: A GRFa2/Prop1/stem (GPS) cell niche in the pituitary. PLoS One 2009; 4:e4815.
28.
Chen M, et al: Coxsackievirus and adenovirus receptor-positive cells compose the putative stem/progenitor cell niches in the marginal cell layer and parenchyma of the rat anterior pituitary. Cell Tissue Res 2013; 354: 823–836.
29.
Susa T, et al: Paired-related homeodomain proteins Prx1 and Prx2 are expressed in embryonic pituitary stem/progenitor cells and may be involved in the early stage of pituitary differentiation. J Neuroendocrinol 2012; 24: 1201–1212.
30.
Gleiberman AS, et al: Genetic approaches identify adult pituitary stem cells. Proc Natl Acad Sci USA 2008; 105: 6332–6337.
31.
Krylyshkina O, et al: Nestin-immunoreactive cells in rat pituitary are neither hormonal nor typical folliculo-stellate cells. Endocrinology 2005; 146: 2376–2387.
32.
Pérez Millán MI, et al: PROP1 triggers epithelial-mesenchymal transition-like process in pituitary stem cells. Elife 2016; 5:e14470.
33.
Jaitin DA, et al: Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell types. Science 2014; 343: 776–779.
34.
Chen J, et al: Spatial transcriptomic analysis of cryosectioned tissue samples with Geo-seq. Nat Protoc 2017; 12: 566–580.
35.
Lovatt D, et al: Transcriptome in vivo analysis (TIVA) of spatially defined single cells in live tissue. Nat Methods 2014; 11: 190–196.
36.
Lee JH, et al: Highly multiplexed subcellular RNA sequencing in situ. Science 2014; 343: 1360–1363.
37.
Livet J, et al: Transgenic strategies for combinatorial expression of fluorescent proteins in the nervous system. Nature 2007; 450: 56–62.
38.
Snippert HJ, et al: Intestinal crypt homeostasis results from neutral competition between symmetrically dividing Lgr5 stem cells. Cell 2010; 143: 134–144.
39.
Carbajo-Pérez E, Watanabe YG: Cellular proliferation in the anterior pituitary of the rat during the postnatal period. Cell Tissue Res 1990; 261: 333–338.
40.
Taniguchi Y, et al: Mitoses of thyrotrophs contribute to the proliferation of the rat pituitary gland during the early postnatal period. Anat Embryol (Berl) 2002; 206: 67–72.
41.
Willems C, et al: Regeneration in the pituitary after cell-ablation injury: time-related aspects and molecular analysis. Endocrinology 2016; 157: 705–721.
42.
Langlais D, et al: Adult pituitary cell maintenance: lineage-specific contribution of self-duplication. Mol Endocrinol 2013; 27: 1103–1112.
43.
Yin P, Kawashima K, Arita J: Direct actions of estradiol on the anterior pituitary gland are required for hypothalamus-dependent lactotrope proliferation and secretory surges of luteinizing hormone but not of prolactin in female rats. Neuroendocrinology 2002; 75: 392–401.
44.
Clevers H, Loh KM, Nusse R: Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014; 346: 1248012.
45.
Gonzalez-Meljem JM, et al: Stem cell senescence drives age-attenuated induction of pituitary tumours in mouse models of paediatric craniopharyngioma. Nat Commun 2017; 8: 1819.
46.
Mertens F, et al: Pituitary tumors contain a side population with tumor stem cell-associated characteristics. Endocr Relat Cancer 2015; 22: 481–504.
47.
Chen J, et al: Pituitary progenitor cells tracked down by side population dissection. Stem Cells 2009; 27: 1182–1195.
48.
Xu Q, et al: Isolation of tumour stem-like cells from benign tumours. Br J Cancer 2009; 101: 303–311.
49.
Chen L, et al: Evidence of brain tumor stem progenitor-like cells with low proliferative capacity in human benign pituitary adenoma. Cancer Lett 2014; 349: 61–66.
50.
Haston S, et al: MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma. Development 2017; 144: 2141–2152.
51.
Lodge EJ, et al: Expression analysis of the Hippo cascade indicates a role in pituitary stem cell development. Front Physiol 2016; 7: 114.
52.
Zhao B, Tumaneng K, Guan KL: The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13: 877–883.
53.
Zanconato F, Cordenonsi M, Piccolo S: YAP/TAZ at the roots of cancer. Cancer Cell 2016; 29: 783–803.
54.
St John MA, et al: Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 1999; 21: 182–186.
55.
Zhao B, et al: TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 1962–1971.
56.
Johnson R, Halder G: The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 2014; 13: 63–79.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.